Common Contracts

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT ASSET PURCHASE AGREEMENT

Asset Purchase Agreement • July 12th, 2013 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware

• Contract Type
  Asset Purchase Agreement
• Filed
  July 12th, 2013
• Company
  Sorrento Therapeutics, Inc.
• Industry
  Services-commercial physical & biological research
• Jurisdiction
  Delaware

THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of March 7, 2013 (“Effective Date”) between IgDraSol, Inc., a Delaware corporation having an office at 11100 Warner Avenue, Suite 266, Fountain Valley, California 92708 (“Seller”) and Sorrento Therapeutics, Inc., a Delaware corporation having an office at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 (“Buyer”).

ASSET PURCHASE AGREEMENT

Asset Purchase Agreement • May 15th, 2013 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware

• Contract Type
  Asset Purchase Agreement
• Filed
  May 15th, 2013
• Company
  Sorrento Therapeutics, Inc.
• Industry
  Services-commercial physical & biological research
• Jurisdiction
  Delaware

THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of March 7, 2013 (“Effective Date”) between IgDraSol, Inc., a Delaware corporation having an office at 11100 Warner Avenue, Suite 266, Fountain Valley, California 92708 (“Seller”) and Sorrento Therapeutics, Inc., a Delaware corporation having an office at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 (“Buyer”).